文献速递乳腺癌

非典型增生女性乳腺癌风险预测模型

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
PubMed 文献 · J Clin Oncol · 2018-04-20

研究利用Mayo良性乳腺疾病队列的回顾性数据,开发并外部验证了专门针对活检诊断为非典型增生(AH)女性的乳腺癌风险预测模型AH-BC。模型仅纳入活检年龄、活检年龄平方和非典型增生灶数量三个协变量,在建模集和外部验证集中均显示出良好的区分度和校准度,可细化该高危亚群的个体化风险预测。

要点

  • AH-BC模型仅基于活检年龄、年龄平方和AH灶数量三个变量。
  • 建模集10年区分度0.63,外部验证集区分度0.59。
  • 模型在建模集和验证集中校准度均可接受。

核心结论

  • AH-BC模型可细化非典型增生女性的乳腺癌风险预测,并在外部数据集中得到验证。

研究设计与样本

  • 回顾性队列研究,建模集来自罗切斯特699例经病理确诊的良性非典型增生女性(18-85岁),外部验证集来自纳什维尔461例同类女性。
  • 采用L1惩罚Cox比例风险回归筛选临床风险因素和组织活检组织学特征,并以死亡为竞争风险拟合Fine and Gray回归模型估计乳腺癌风险。
  • 在建模集和外部验证集中评估模型的区分度和校准度。

主要发现

  • 建模集699例中142例发生乳腺癌,中位随访8.1年;外部验证集461例中114例 later BC事件,中位随访11.4年。
  • 最终AH-BC模型包含三个协变量:活检时年龄、活检时年龄的平方、非典型增生灶数量。
  • 建模集10年区分度为0.63(95% CI,0.57至0.70),校准度为0.87(95% CI,0.66至1.24)。
  • 外部验证集区分度为0.59(95% CI,0.51至0.67),校准度为0.91(95% CI,0.65至1.42)。

临床怎么用

  • 对于活检证实为非典型增生的女性,可采用AH-BC模型基于活检年龄和AH灶数量进行个体化乳腺癌风险分层。
  • 模型区分度在外部验证集中为0.59,临床使用时需结合其他临床因素综合判断。

局限性

  • 建模集和验证集均为回顾性队列,可能存在选择偏倚和信息偏倚。
  • 外部验证集区分度(0.59)低于建模集(0.63),泛化能力有限。
  • 模型仅纳入三个协变量,未包含其他潜在风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do not provide accurate individualized estimates of risk in this subset of high-risk women. Here, we used the Mayo benign breast disease cohort to develop and validate a model of BC risk prediction that is specifically for women with AH, which we have designated as AH-BC. Patients and Methods Retrospective cohorts of women age 18 to 85 years with pathologically confirmed benign AH from Rochester, MN, and Nashville, TN, were used for model development and external validation, respectively. Clinical risk factors and histologic features of the tissue biopsy were selected using L1-penalized Cox proportional hazards regression. Identified features were included in a Fine and Gray regression model to estimate BC risk, with death as a competing risk. Model discrimination and calibration were assessed in the model-building set and an external validation set. Results The model-building set consisted of 699 women with AH, 142 of whom developed BC (median follow-up, 8.1 years), and the external validation set consisted of 461 women with 114 later BC events (median follow-up, 11.4 years). The final AH-BC model included three covariates: age at biopsy, age at biopsy squared, and number of foci of AH. At 10 years, the AH-BC model demonstrated good discrimination (0.63 [95% CI, 0.57 to 0.70]) and calibration (0.87 [95% CI, 0.66 to 1.24]). In the external validation set, the model showed acceptable discrimination (0.59 [95% CI, 0.51 to 0.67]) and calibration (0.91 [95% CI, 0.65 to 1.42]). Conclusion We have created a new model with which to refine BC risk prediction for women with AH. The AH-BC model demonstrates good discrimination and calibration, and it validates in an external data set.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Degnim AC, Winham SJ, Frank RD, et al. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol. 2018. PMID: 29676945. doi:10.1200/JCO.2017.75.9480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。